Trillium Therapeutics Announces Presentation on TTI-621 Immune Checkpoint Inhibitor Targeting CD47 at European Hematology Association 21st Annual Congress

ID: 1439840
recent pressrelease next pressrelease

(businesspress24) - TORONTO, ONTARIO -- (Marketwired) -- 06/07/16 -- Trillium Therapeutics Inc. (NASDAQ: TRIL)(TSX: TR), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, will present its TTI-621 (SIRPaFc) immune checkpoint inhibitor program at the European Hematology Association 21(st) Annual Congress, to be held in Copenhagen from June 9-12.

Details of Trillium''s presentation are as follows:

Presentation Type: Electronic Poster

Abstract #: E1373

Title: The CD47-blocking Cancer Immunotherapeutic TTI-621 has Anti-Tumor Effects Across a Broad Range of Hematological Malignancies

About Trillium Therapeutics

Trillium Therapeutics Inc. is a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. The company''s lead program, SIRPaFc, is a fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin. It is designed to act as a soluble decoy receptor, preventing CD47 from delivering its inhibitory ("do not eat") signal. Neutralization of the inhibitory CD47 signal enables the activation of macrophage anti-tumor effects by pro-phagocytic ("eat") signals. A Phase I clinical trial () evaluating SIRPaFc (TTI-621) is ongoing. Trillium also has a proprietary medicinal chemistry platform, using unique fluorine chemistry, which permits the creation of new chemical entities from validated drugs and drug candidates with improved pharmacological properties. Stemming from this platform, the company''s most advanced preclinical program is an orally-available bromodomain inhibitor, followed by an epidermal growth factor receptor antagonist with increased uptake in the brain. In addition, a number of compounds directed at undisclosed immuno-oncology targets are currently in the discovery phase.

For more information visit: .

Caution Regarding Forward-Looking Information

This press release may contain forward-looking statements, which reflect Trillium''s current expectation regarding future results, events or developments. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such risks and uncertainties are described in the company''s ongoing quarterly and annual reporting. Except as required by applicable securities laws, Trillium undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Neither TSX nor its Regulation Services Provider (as that term is defined in the policies of the TSX) accepts responsibility for the adequacy or accuracy of this release.

Contacts:


Trillium Therapeutics Inc.
James Parsons
Chief Financial Officer
416-595-0627 x232



Investor and Media Relations:
Canale Communications for Trillium Therapeutics
Mark Corbae
619-849-5375



More information:
http://www.realwire.com/releases/Vectra-Networks-Enables-Organisations-to-Stem-the-Ransomware-Pandemic http://www.acrylicdisplay.com.hk http:// https://blogit.realwire.com/ZIRA-and-Saudi-Telecom-Company-Win-Global-Telecoms-Business-Innovation-Award https:



Keywords (optional):

trillium-therapeutics-inc,



Company information / Profile:

PressRelease by

Requests:



PressContact / Agency:



published by: Marketwired
print pressrelease  send to a friend  

Date: 06/07/2016 - 05:00
Language: English
News-ID 1439840
Character count: 3465
Kontakt-Informationen:
Firma: Trillium Therapeutics Inc.
Ansprechpartner: Feedback to businesspress24.com about Pressrelease-id:
Stadt: TORONTO, ONTARIO
Telefon:

Meldungsart:
Versandart:
Freigabedatum:
Comments:



Number of hits: 198

Linking-Tips:



Direct Link to this PressRelease:






We would appreciate a link in your News-, Press- or Partner-Site.

Comments on this PressRelease






All members: 9 438
Register today: 0
Register yesterday: 0
Members online: 0
Guests online: 70


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.